Avicanna (AVCNF)
OTHER OTC:AVCNF
AVCNF Stock Chart & Stats
$0.16
<$0.01(4.49%)
At close: 4:00 PM EST
$0.16
<$0.01(4.49%)
Day’s Range― - ―
52-Week Range$0.10 - $0.25
Previous CloseN/A
Volume3.00K
Average Volume (3M)67.97K
Market Cap
$13.56M
Enterprise Value$18.37M
Total Cash (Recent Filing)$464.85K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,683,370
10 Day Avg. Volume90,556
30 Day Avg. Volume67,972
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)13.19
Price to Sales (P/S)1.20
P/FCF Ratio-10.34
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit1.38
Enterprise Value/Ebitda-17.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthNearly 48% TTM revenue growth indicates accelerating market adoption of Avicanna’s cannabinoid product lines and B2B services. Sustained top-line expansion supports scale benefits, helps absorb fixed costs, and creates durable optionality to fund R&D and commercial expansion over the next several quarters.
Margin ImprovementA jump to ~52% gross margin from ~40% suggests structural improvement in product mix, higher-value formulations, or pricing power tied to IP and formulation capabilities. Higher durable gross margins increase the potential to convert revenue scale into lasting operating profitability as overhead is leveraged.
Cleaner Balance SheetA positive equity position and reported zero debt materially lower solvency risk and interest burden. This improved financial flexibility supports strategic partnerships, manufacturing investments and R&D without immediate refinancing pressure, aiding medium-term operational stability.
Bears Say
Negative Cash Flow & ProfitabilityMargins remain negative (~-7%) and the company is still a net cash user, with TTM operating and free cash flow deficits. Persistent cash burn constrains reinvestment in commercialization and R&D, increases dependency on external capital, and delays the timeline for sustained, internally financed profitability.
Weak Returns / Small Equity CushionAlthough equity is positive, its modest size and negative ROE show invested capital hasn’t produced returns yet. A thin equity base provides limited buffer against further losses or large investments, raising vulnerability to shocks and constraining the company’s ability to fund growth without dilutive financing.
Reliance On External FinancingThe pack explicitly notes the business is not self-funding and will likely need external financing or material cost/revenue improvements. Dependence on outside capital increases execution risk, potential shareholder dilution, and sensitivity to capital-market conditions over the medium term.
Avicanna News
AVCNF FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was $0.10 and its highest was $0.25 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is $13.56M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is May 18, 2026 which is in 50 days.
How were Avicanna’s earnings last quarter?
Currently, no data Available
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,683,370 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in AVCNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Ownership Overview
28.11% Insiders
<0.01% Other Institutional Investors
71.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---